The Ever-Increasing Array of Novel Inborn Errors of Immunity: an Interim Update by the IUIS Committee is a research paper published in Journal of Clinical Immunology (2021). On theSindex it has a DataRank of 0.806. It has been cited 215 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.806
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →NIAID NIH HHS
Grant: P01 AI061093
FWCI
14.83
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Additional file 1 of Growth in diagnosis and treatment of primary immunodeficiency within the global Jeffrey Modell Centers Network
Additional file 1 of Growth in diagnosis and treatment of primary immunodeficiency within the global Jeffrey Modell Centers Network
Additional file 2 of Growth in diagnosis and treatment of primary immunodeficiency within the global Jeffrey Modell Centers Network
Additional file 2 of Growth in diagnosis and treatment of primary immunodeficiency within the global Jeffrey Modell Centers Network
Additional file 1 of Flow cytometry optimizing the diagnostic approach in inborn errors of immunity: experience from Egypt
Additional file 1 of Flow cytometry optimizing the diagnostic approach in inborn errors of immunity: experience from Egypt
Additional file 1 of Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real-world study
Additional file 1 of Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real-world study
Additional file 2 of Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real-world study
Additional file 2 of Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real-world study